BM7046 - Cancer: Diagnosis and Therapy (2022/23)
|Module specification||Module approved to run in 2022/23|
|Module title||Cancer: Diagnosis and Therapy|
|Module level||Masters (07)|
|Credit rating for module||20|
|School||School of Human Sciences|
|Total study hours||200|
|Running in 2022/23(Please note that module timeslots are subject to change)||
This module provides an understanding of the clinical aspects of oncology, focusing on diagnosis and staging of different cancers, and the range of options open for therapy.
The aim of this module is to give a synopsis of the major cancers from the perspective of a diagnostician, thus providing a background to other modules on this course which focus on molecular and pharmacological aspects of the disease.
• Cancer – an overview
• Staging and grading of malignancies
• Principles of cancer therapy (radiotherapy, surgery, chemotherapy, endocrine, biologic therapies)
• Cancers of the head and neck, lung, gastrointestinal tract, breast, reproductive organs, central nervous system, endocrine system, skin, blood; sarcomas.
Balance of independent study and scheduled teaching activity
Students will be guided in their learning using a combination of private study, interactive lectures and small group tutorials exploring realistic problems/case studies. Preparation for assignments will enable students to reinforce and expand their knowledge base and develop subject skills and competences. They will be able to assess and reflect upon their understanding of the material through the completion on-line quizzes.
On successful completion of this module, students will be able to:
1. demonstrate a critical awareness of the general principles of cancer diagnosis;
2. differentiate between available treatment options open to clinicians in patient case
Studies and develop and demonstrate a deep and systematic understanding of key cancers and cancer therapies.
3. evaluate published relevant research material and put together a balanced review of a
selected topic; relating to cancer diagnosis and therapy using up-to-date primary
The module will be summatively assessed by the analysis of a case study (50%), and by an end of module test (50%) comprising short answer questions.
To pass the module students need to achieve a minimum aggregate mark of 50%.
Component Learning outcomes
British Journal of Cancer
European Journal of Cancer
British Journal of Clinical Pharmacology